H.C. Wainwright raised the firm’s price target on DiaMedica Therapeutics (DMAC) to $12 from $10 and keeps a Buy rating on the shares. The firm says that with the positive interim results from Part 1a of the Phase 2 study, there is “tangible evidence” for the therapeutic potential of DM199 across achieved pre-specified efficacy and safety endpoints from the dose escalation.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DMAC:
- DiaMedica Announces Positive Interim Results for DM199 Study
- DiaMedica Therapeutics reports interim results from DM199 study
- ReMEDy2 Trial: A New Hope for Acute Ischemic Stroke Treatment
- DiaMedica Therapeutics to be included in Russell 2000, 3000 Indexes
- Promising Potential of Diamedica Therapeutics’ DM199 in Preeclampsia Treatment Drives Buy Rating